当前位置:
X-MOL 学术
›
Human Psychopharmacology: Clinical and Experimental
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study
Human Psychopharmacology: Clinical and Experimental ( IF 1.672 ) Pub Date : 2021-01-26 , DOI: 10.1002/hup.2777 Jun Ishigooka 1 , Ken Inada 2 , Kazunari Niidome 3 , Kazuo Aoki 3 , Yoshitsugu Kojima 3 , Shuichi Iwashita 4 , Sakiko Yamada 3
Human Psychopharmacology: Clinical and Experimental ( IF 1.672 ) Pub Date : 2021-01-26 , DOI: 10.1002/hup.2777 Jun Ishigooka 1 , Ken Inada 2 , Kazunari Niidome 3 , Kazuo Aoki 3 , Yoshitsugu Kojima 3 , Shuichi Iwashita 4 , Sakiko Yamada 3
Affiliation
To determine the long-term safety of switching to brexpiprazole from aripiprazole or non-aripiprazole dopamine antagonists.
中文翻译:
日本精神分裂症患者改用 brexpiprazole 的安全性:一项长期开放标签研究的事后分析
确定从阿立哌唑或非阿立哌唑多巴胺拮抗剂改用brexpiprazole 的长期安全性。
更新日期:2021-01-26
中文翻译:
日本精神分裂症患者改用 brexpiprazole 的安全性:一项长期开放标签研究的事后分析
确定从阿立哌唑或非阿立哌唑多巴胺拮抗剂改用brexpiprazole 的长期安全性。